SE467910B - Lyofiliserad eller faelld kombination cefalosporin-zwitterjon och salt - Google Patents

Lyofiliserad eller faelld kombination cefalosporin-zwitterjon och salt

Info

Publication number
SE467910B
SE467910B SE8800036A SE8800036A SE467910B SE 467910 B SE467910 B SE 467910B SE 8800036 A SE8800036 A SE 8800036A SE 8800036 A SE8800036 A SE 8800036A SE 467910 B SE467910 B SE 467910B
Authority
SE
Sweden
Prior art keywords
zwitterion
chloride
antibiotic composition
molar ratio
sodium
Prior art date
Application number
SE8800036A
Other languages
English (en)
Swedish (sv)
Other versions
SE8800036L (sv
SE8800036D0 (sv
Inventor
M A Kaplan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SE8800036D0 publication Critical patent/SE8800036D0/xx
Publication of SE8800036L publication Critical patent/SE8800036L/
Publication of SE467910B publication Critical patent/SE467910B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
SE8800036A 1987-01-09 1988-01-08 Lyofiliserad eller faelld kombination cefalosporin-zwitterjon och salt SE467910B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/001,945 US4808617A (en) 1985-12-18 1987-01-09 Lyophilized or precipitated cephalosporin zwitterion and salt combination

Publications (3)

Publication Number Publication Date
SE8800036D0 SE8800036D0 (sv) 1988-01-08
SE8800036L SE8800036L (sv) 1988-07-10
SE467910B true SE467910B (sv) 1992-10-05

Family

ID=21698538

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8800036A SE467910B (sv) 1987-01-09 1988-01-08 Lyofiliserad eller faelld kombination cefalosporin-zwitterjon och salt

Country Status (33)

Country Link
US (1) US4808617A (nl)
JP (1) JP2568226B2 (nl)
KR (1) KR950010154B1 (nl)
AR (1) AR243501A1 (nl)
AT (1) AT388672B (nl)
AU (1) AU606361B2 (nl)
BE (1) BE1002114A3 (nl)
CA (1) CA1307464C (nl)
CH (1) CH676202A5 (nl)
CS (1) CS265249B2 (nl)
CY (1) CY1679A (nl)
DD (1) DD264614A5 (nl)
DE (1) DE3740588C2 (nl)
DK (1) DK166404B1 (nl)
ES (1) ES2008951A6 (nl)
FI (1) FI89006C (nl)
FR (1) FR2609396B1 (nl)
GB (1) GB2199746B (nl)
GR (1) GR871860B (nl)
HK (1) HK5593A (nl)
HU (1) HU199686B (nl)
IE (1) IE61238B1 (nl)
IL (1) IL84346A (nl)
IT (1) IT1215666B (nl)
LU (1) LU87102A1 (nl)
NL (1) NL193266C (nl)
OA (1) OA08796A (nl)
PT (1) PT86157B (nl)
SE (1) SE467910B (nl)
SG (1) SG114792G (nl)
SU (1) SU1575942A3 (nl)
YU (1) YU46689B (nl)
ZA (1) ZA88114B (nl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910301A (en) * 1985-08-05 1990-03-20 Bristol-Myers Company Cefepime cephalosporin salts
CA2011116C (en) * 1989-03-06 1999-11-16 Murray A. Kaplan Lyophilized bmy-28142 dihydrochloride for parenteral use
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
WO2005094800A2 (en) * 2004-03-31 2005-10-13 Lupin Ltd. A co-precipitated cefepime composition and process for preparation thereof
WO2006109324A2 (en) * 2005-04-13 2006-10-19 Lupin Limited Processes for preparation of amorphous cefepime acid addition salts
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
CA2906151A1 (en) 2013-03-15 2014-09-18 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
JP6218204B2 (ja) 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953439A (en) * 1973-08-01 1976-04-27 Smithkline Corporation Substituted phenylglycylcephalosporins
US4029655A (en) * 1975-04-11 1977-06-14 Eli Lilly And Company Method of preparing stable sterile crystalline cephalosporins for parenteral administration
US4406899A (en) * 1982-03-04 1983-09-27 Bristol-Myers Company Cephalosporins
CA1213882A (en) * 1982-03-04 1986-11-12 Jun Okumura Cephalosporins
JPS6045514A (ja) * 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
US4604386A (en) * 1984-07-09 1986-08-05 Eli Lilly And Company 3-(alkynylalkyloxy) cephalosporins
JPS61130223A (ja) * 1984-11-28 1986-06-18 Shionogi & Co Ltd 抗菌性凍結乾燥製剤
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions

Also Published As

Publication number Publication date
GB2199746B (en) 1990-10-24
NL193266B (nl) 1999-01-04
GR871860B (en) 1988-05-10
DK166404B1 (da) 1993-05-17
CA1307464C (en) 1992-09-15
AU606361B2 (en) 1991-02-07
NL8800025A (nl) 1988-08-01
SE8800036L (sv) 1988-07-10
CY1679A (en) 1993-10-10
FR2609396A1 (fr) 1988-07-15
NL193266C (nl) 1999-05-06
OA08796A (fr) 1989-03-31
FI875122A (fi) 1988-07-10
US4808617A (en) 1989-02-28
ATA341687A (de) 1989-01-15
BE1002114A3 (fr) 1990-07-10
HU199686B (en) 1990-03-28
IL84346A (en) 1992-05-25
SG114792G (en) 1992-12-24
HK5593A (en) 1993-02-05
DK577387A (da) 1988-07-10
PT86157A (en) 1987-12-01
HUT46223A (en) 1988-10-28
IT1215666B (it) 1990-02-22
FI89006C (fi) 1993-08-10
JP2568226B2 (ja) 1996-12-25
AU8085687A (en) 1989-05-11
JPS63208522A (ja) 1988-08-30
FR2609396B1 (fr) 1993-01-29
GB2199746A (en) 1988-07-20
SE8800036D0 (sv) 1988-01-08
GB8725875D0 (en) 1987-12-09
CS15888A2 (en) 1989-01-12
DE3740588C2 (de) 1996-07-11
DE3740588A1 (de) 1988-07-21
KR880008811A (ko) 1988-09-13
AR243501A1 (es) 1993-08-31
CH676202A5 (nl) 1990-12-28
SU1575942A3 (ru) 1990-06-30
DD264614A5 (de) 1989-02-08
PT86157B (pt) 1991-02-08
CS265249B2 (en) 1989-10-13
IE872970L (en) 1988-07-09
IL84346A0 (en) 1988-04-29
ZA88114B (nl) 1988-06-27
FI89006B (fi) 1993-04-30
LU87102A1 (fr) 1988-08-23
KR950010154B1 (ko) 1995-09-11
IE61238B1 (en) 1994-10-19
AT388672B (de) 1989-08-10
FI875122A0 (fi) 1987-11-19
YU2388A (en) 1989-10-31
ES2008951A6 (es) 1989-08-16
DK577387D0 (da) 1987-11-03
YU46689B (sh) 1994-04-05
IT8819013A0 (it) 1988-01-07

Similar Documents

Publication Publication Date Title
SE467910B (sv) Lyofiliserad eller faelld kombination cefalosporin-zwitterjon och salt
US3801633A (en) N-substituted amino acids having antiviral effects
NL192266C (nl) Werkwijze voor het bereiden van een kristallijn cefepime-dihydrochloride alsmede het kristallijne dihydrochloride en mengsels die het bevatten.
IE861984L (en) Crystalline salt of guanine derivative
KR101455208B1 (ko) 안정적인 ｓ-아데노실메티오닌의 염 및 이를 제조하기 위한 방법
JPH045038B2 (nl)
DK163032B (da) Lyofiliseret antibakterielt praeparat indeholdende 7beta-difluormethylthioacetamido-7alfa-methoxy-3-oe1-(2-hydroxyalkyl)-1h-tetrazol-5-ylaa-thiomethyl-1-dethia-1-oxa-3-cephem-4-carboxylsyrealkalimetalsalt samt fremgangsmaade til fremstilling af praeparatet
KR20170032348A (ko) 저 치환된 폴리믹신 및 이의 조성물
CA1134269A (en) Synergistic mixtures
EP0189942B1 (en) Cefbuperazone crystalline triethylamine salt
CA2011116C (en) Lyophilized bmy-28142 dihydrochloride for parenteral use
JPS58103392A (ja) ３位においてチオメチルヘテロ環基により置換されたセフアロスポリンの新規な誘導体、これら化合物の製造方法およびこれらを含有する薬学的組成物
CA1307206C (en) Antibacterial agent for mammal use comprising cephalosporin derivatives as an effective ingredient
US3925352A (en) L-aspartate of cyclic erythromycin a carbonate and process of preparing the same
EP0351795A2 (en) Novel deoxyadenosine compounds and methods of making and using the same
US3531460A (en) Erythromycin tetracycline containing antibiotic derivatives
KR800000604B1 (ko) 비경구용 0-포밀세파만돌 나트륨염제제의 제조방법
JPH0150235B2 (nl)
JPS6310158B2 (nl)
JPH05178743A (ja) エイズウイルス感染阻害剤
JPH0443074B2 (nl)

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8800036-9

Format of ref document f/p: F

NUG Patent has lapsed